NorthWest Biotherapeutics Inc (NWBO)

[jm100]

Neon Therapeutics (NTGN) said Monday that a phase 1b trial evaluating its NEO-PV-01 vaccine combined with Bristol-Myers Squibb's Opdivo showed prolonged median progression-free survival, or PFS, in multiple types of cancer.

The company evaluated the drug combination in patients with advanced or metastatic melanoma, smoking-associated non-small cell lung cancer and bladder cancer.

At 13.4-month median follow-up in 34 patients with metastatic melanoma, median PFS had not yet been reached. In 27 patients with metastatic NSCLC, median PFS was 5.6 months, and in 21 patients with metastatic bladder cancer, median PFS was 5.6 months.

Neon said the data support further development of the vaccine, including randomized phase 2 trials.